XXII. Evaluation of drug efficacy by using animal models or in vitro systems

FEMS Immunology and Medical Microbiology

Volumn 22, Issue 1-2, 1998, Pages 173-179

  Brun Pascaud, Monique ^a   Herreros, Esperanza ^b   Aliouat, El Moukhtar ^b   Dei Cas, Eduardo ^c,d  

^a BICHAT HOSPITAL   (France)

^b GLAXOSMITHKLINE   (Spain)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Co infection model; Corticosteroid treated rat; Metabolism; Nude rat; Pneumocystis drug assay; Radiolabeled precursor

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DEFEROXAMINE; EFLORNITHINE; PENTAMIDINE; PNEUMOCANDIN DERIVATIVE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; DRUG SCREENING; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; TOXOPLASMOSIS; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; EVALUATION; HUMAN; METHODOLOGY; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; EVALUATION STUDIES; HUMANS; MYCOBACTERIUM INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; TOXOPLASMOSIS;

EID: 0032148383     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(98)00076-5     Document Type: Conference Paper

References (55)

1. Dei-Cas, E., Mazars, E., Aliouat, E.M., Nevez, G., Cailliez, J.C. and Camus, D. (1998) The host-specificity of Pneumocystis carinii. J. Mycol. Med. 8, 1-6.
2. Tsolaki, A.G., Miller, R.F., Underwood, A.P., Banerji, S. and Wakefield, A.E. (1996) Genetic diversity at the internal transcribed spacer regions of the ribosomal RNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J. Infect. Dis. 174, 141-156.
3. Cushion, M.T., Kaselis, S.L., Stringer, S.L. and Stringer, J.R. (1993) Genetic stability and diversity of Pneumocystis carinii infecting rat colonies. Infect. Immun. 61, 4801-4813.
4. Mazars, E., Guyot, K., Durand, I., Dei-Cas, E., Boucher, S., Ben Abderrazak, S., Banuls, A.L., Tibayrenc, M. and Camus, D. (1997) Isoenzyme diversity in Pneumocystis carinii from rats, mice and rabbits. J. Infect. Dis. 175, 655-660.
5. Aliouat, E.M., Dei-Cas, E., Ouaissi, M.A., Palluault, F., Soulez, B. and Camus, D. (1993) In vitro attachment of Pneumocystis carinii from mouse and rat origin. Biol. Cell 77, 209-217.
6. Debs, R., Straubinger, M., Brunette, E., Lin, J., Lin, E., Montgomery, A., Friend, D. and Papahadjopoulos, D. (1987) Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am. Rev. Respir. Dis. 135, 731-737.
7. Farinotti, R., Brun-Pascaud, M., Girard, P.M., Guillot, E., Certain, A. and Trouvin, J.H. (1989) Comparison of tissular disposition of pentamidine mesylate in the rat after aerosol parenteral administration. J. Infect. Dis. 160, 507-512.
8. Debs, R., Blumenfeld, W., Brunette, E., Straubinger, M., Montgomery, A., Lin, E., Agabian, N. and Papahadjopoulos, D. (1987) Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother. 31, 37-41.
9. Girard, P.M., Brun-Pascaud, M., Farinotti, R., Tamissier, L. and Kernbaum, S. (1987) Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 31, 978-981.
10. Schmatz, D.M., Powles, M.A., McFadden, D.C., Pittarelli, L., Balkovec, J., Hammond, M., Zambias, R., Liberator, P. and Andersen, J. (1992) Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob. Agents Chemother. 36, 1964-1970.
11. Powles, M.A., McFadden, D., Liberator, P., Anderson, J., Vadas, E., Meisner, D. and Schmatz, D.M. (1994) Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats. Antimicrob. Agents Chemother. 38, 1397-1401.
12. Schmatz, D.M., Powles, M.A., McFadden, D., Nollstadt, K., Bouffard, A.F., Dropinski, J.F., Liberator, P. and Andersen, J. (1995) New semisynthetic Pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob. Agents Chemother. 39, 1320-1323.
13. Shear, H.L., Valladares, G. and Narachi, M.A. (1990) Enhanced treatment of Pneumocystis carinii pneumonia in rats with Interferon-gamma and reduced doses of Trimethoprim/Sulfamethoxazole. J. Acquired Immune Defic. Syndr. 3, 943-948.
14. Merali, S., Chin, K., Grady, R.W., Weissberger, L. and Clarkson, A.B. (1995) Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of Deferoxamine. Antimicrob. Agents Chemother. 39, 1442-1444.
15. Merali, S., Chin, K., Der Angel, L., Grady, R.W., Armstrong, M. and Clarkson, A.B. (1995) Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 39, 2023-2026.
16. Clarkson, A.B., Williams, D.E. and Rosemberg, C. (1988) Efficacy of DL-α-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 32, 1158-1163.
17. Clarkson, A., Saric, M. and Grady, R. (1990) Deferoxamine and eflornithine (DL-α-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 34, 1833-1835.
18. Chin, K., Merali, S., Saric, M. and Clarkson, A.B. (1996) Continuous infusion of DL-α-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 40, 2318-2320.
19. Bartlett, M.S., Fishman, J.A., Durkin, M.M., Queener, S.F. and Smith, J.W. (1990) Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis carinii pneumonia in the rat (Rattus spp.). Exp. Parasitol. 70, 100-106.
20. Hughes, W.T. and Smith, B.L. (1983) Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 24, 300-301.
21. Hughes, W.T., Killmar, J.T. and Oz, H.S. (1994) Relative potency of 10 drugs with anti-Pneumocystis carinii activity in animal model. J. Infect. Dis. 170, 906-911.
22. Hughes, W.T. and Killmar, J. (1996) Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 40, 962-965.
23. Viora, M., De Luca, A., D'Ambrosio, A., Antinori, A. and Ortona, E. (1996) In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob. Agents Chemother. 40, 1294-1297.
24. Oz, H.S., Hughes, W.T. and Rehg, J.E. (1997) Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 41, 191-192.
25. Walzer, P.D., Kim, C.K., Foy, J.M. and Zhang, J. (1991) Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 35, 158-163.
26. Walzer, P.D., Foy, J., Steele, P. and White, M. (1992) Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother. 36, 1943-1950.
27. Walzer, P.D., Foy, J., Steele, P., Kim, C.K., White, M., Klein, R.S., Otter, B.A. and Allegra, C. (1992) Activities of antifolate, antiviral and others in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36, 1935-1942.
28. Walzer, P.D., Runck, J., Orr, S., Foy, J., Steele, P. and White, M. (1997) Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. Antimicrob. Agents Chemother. 41, 242-250.
29. Queener, S., Dean, R., Bartlett, M.S., Milhous, W., Berman, J. and Ellis, W. (1992) Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats. J. Infect. Dis. 165, 764-768.
30. Bartlett, M.S., Queener, S.F., Tidwell, R.R., Milhous, W.K., Berman, J.D., Ellis, W.Y. and Smith, J.W. (1991) 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystosis pneumonia in rat models. Antimicrob. Agents Chemother. 35, 277-282.
31. Bartlett, M.S., Queener, S.F., Shaw, M.M., Richardson, J.D. and Smith, J.W. (1994) Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob. Agents Chemother. 38, 1859-1861.
32. Contini, C., Colombo, D., Cultrera, R., Prini, E., Sechi, T., Angelici, E. and Canipari, R. (1996) Employment of terbinafine against Pneumocystis carinii infection in rat models. Br. J. Dermatol. 134, 30-32.
33. Brun-Pascaud, M., Chau, F., Simonpoli, A.M., Girard, P.M., Derouin, F. and Pocidalo, J.J. (1994) Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J. Infect. Dis. 170, 653-658.
34. Brun-Pascaud, M., Chau, F., Derouin, F. and Girard, P.M. (1996) Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model. J. Eukaryotic Microbiol. 43, 14-15S.
35. Brun-Pascaud, M., Chau, F., Garry, L., Jacobus, D., Derouin, F. and Girard, P.M. (1996) Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infections in a rat model. Antimicrob. Agents Chemother. 40, 2067-2070.
36. Brun-Pascaud, M., Chau, F., Derouin, F. and Girard, P.M. (1996) Altered trimethoprim/sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. J. Acquired Immune Defic. Syndr. 13, 201-207.
37. Brun-Pascaud, M., Chau, F., Derouin, F. and Girard, P.M. (1997) Experimental evaluation of roxithromycin combined with dapsone or sulfamethoxazole on pneumocystosis and toxoplasmosis dual infections in rat model. J. Antimicrob. Chemother., in press.
38. Soulez, B., (1991) Morphological evaluation of Pneumocystis carinii after extraction from infected lung. J. Parasitol. 77, 449-453.
39. Frenkel, J.K., Good, J.T. and Schultz, J.A. (1966) Latent pneumocystis infection in rats, relapse and chemotherapy. Lab. Invest. 15, 1559-1577.
40. Bartlett, M.S., Fishman, J.A., Queener, S.F., Durkin, M.M., Jay, M.A. and Smith, J.W. (1988) New rat model of Pneumocystis carinii infection. J. Clin. Microbiol. 26, 1100-1102.
41. Araujo, F.G., Huskinson, J. and Remington, J.S. (1991) Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35, 293-299.
42. Derouin, F., Piketty, C., Chastang, C., Chau, F., Rouveix, B. and Pocidalo, J.J. (1991) Antitoxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob. Agents Chemother. 35, 252-255.
43. Perronne, C., Cohen, Y., Truffot-Pernot, C., Grosset, J., Vildé, J.L. and Pocidalo, J.J. (1992) Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob. Agents Chemother. 36, 2408-2412.
44. Gangadharam, P.R. (1995) Beige mouse model for Mycobacterium avium complex disease. Antimicrob. Agents Chemother. 39, 1647-1654.
45. Brun-Pascaud, M., Chau, F., Simonpoli, A.M., Girard, P.M., Derouin, F. and Pocidalo, J.J. (1994) Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J. Infect. Dis. 170, 653-658.
46. Brun-Pascaud, M., Bertrand, G., Chau, F., Rajagopalan-Levasseur, P., Garry, L., Derouin, F. and Girard, P.M. (1996) Rat model of concurrent Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and Mycobacterium avium Complex (MAC) infections for assessment of multiple prophylaxis. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Abstract I096.
47. Pesanti, E.L. and Cox, C. (1981) Metabolic and synthetic activities of Pneumocystis carinii in vitro. Infect. Immun. 34, 908-914.
48. Cushion, M.T. and Ebbets, D. (1991) Growth and metabolism of Pneumocystis carinii in axenic culture. J. Clin. Microbiol. 28, 1385-1394.
49. Kovacs, J.A., Allegra, C.J., Beaver, J., Boarman, D., Lewis, M., Parillo, J.E., Chabner, B. and Masur, H. (1989) Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii. Potential for screening therapeutic agents. J. Infect. Dis. 160, 312-320.
50. Comley, J.C.W., Mullin, R.J., Wolfe, L.A., Hanlon, M.H. and Ferone, R. (1991) Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrob. Agents Chemother. 35, 1965-1974.
51. Martinez, A. and Kovacs, J.A. (1993) Development and characterization of a rapid screening assay for identifying antipneumocystis agents. Antimicrob. Agents Chemother. 37, 1674-1678.
52. Bishop, R.L., Jackson, H.C. and Warhurst, D.C. (1994) Measurement of protein biosynthesis in Pneumocystis carinii to investigate the effects of translation-specific inhibitors. J. Eukaryotic Microbiol. 41, 76S-78S.
53. Herreros, E., Amela, M.J., Martinez, M., Lozano, S., Jackson, H., Aliouat, E.M. and Gargallo, D. (1997) Microplate assays for in vitro evaluation of anti-Pneumocystis drugs, abstr. P17. In: Program and Abstracts of the Fifth International Workshop on Opportunistic Protists and Fifth Meeting of the European Concerted Action on Pneumocystis Research, Lille, France.
54. Cushion, M.T., Stanforth, D., Linke, M.J. and Walzer, P.D. (1985) Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother. 28, 796-801.
55. Cushion, M.T., Chen, F. and Kloepfer, N. (1997) A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob. Agents Chemother. 41, 379-384.